Refractory primary immune thrombocytopenia and use of combined therapy, case report

Authors

  • Alex Jhonier Imbachí Salamanca Universidad del Cauca, Colombia
  • Juan David Orozco Burbano Universidad del Cauca, Colombia
  • Mario Ernesto Correa Correa Universidad del Cauca, Colombia

DOI:

https://doi.org/10.14482/sun.39.02.400.573

Keywords:

thrombocytopenia, hemorrhage, glucocorticoids, splenectomy, Rituximab, combined modality therapy.

Abstract

Primary immune thrombocytopenia is an acquired autoimmune disorder, characterized by platelet
destruction, resulting from the production of antibodies against the platelet membrane,
involving a high risk of bleeding for the patient. Currently, the cornerstone of treatment is the use
of first-line agents such glucocorticoids and intravenous immunoglobulin. However, in some
patients may be refractory to these agents, requiring the use of second and third line agents.
We present the case of a 25-year-old female patient with a history of primary immune thrombocytopenia
with severe presentation due to the presence of gastrointestinal bleeding and associated
anemic state, with refractoriness to different treatment including splenectomy and
the subsequent use of Rituximab, which was used to maintain an adequate platelet count. We
consider that this case is of clinical interest given the scarce case reports of this condition and
the limited evidence on sequential therapies in patients refractory to first line treatment.

Author Biographies

Published

2023-09-18

Issue

Section

CLINICAL CASE REPORTS

How to Cite

Refractory primary immune thrombocytopenia and use of combined therapy, case report. (2023). SCIENTIFIC JOURNAL SALUD UNINORTE, 39(2), 818-826. https://doi.org/10.14482/sun.39.02.400.573

Similar Articles

1-10 of 96

You may also start an advanced similarity search for this article.